Lethal-7-related polymorphisms are associated with susceptibility to and prognosis of gastric cancer

Table 5 Associations between clinical factors and overall survival of gastric cancer patients

Variable	Classification	na	Death (%)	5-yr survival (%)	P valueb
Age (yr)	≤ 65	494	197 (39.9)	59.7 (55.0-64.0)	< 0.001
	> 65	241	137 (56.8)	42.3 (35.6-48.8)
Gender	Female	195	82 (42.1)	56.8 (49.2-63.7)	0.261
	Male	540	252 (46.7)	52.9 (48.4-57.2)
Differentiation	Poor	508	241 (47.4)	50.9 (46.2-55.3)	0.010
	Moderate and high	209	85 (40.7)	61.6 (54.4-68.0)
WHO type	Tubular adenocarcinoma	614	275 (44.8)	54.8 (50.6-58.8)	0.205
	Signet ring cell	72	32 (44.4)	52.8 (39.8-64.2)
	Other	45	25 (55.6)	44.5 (29.2-58.6)
T stage	T1	100	13 (13.0)	85.8 (76.5-91.6)	< 0.001
	T2	102	16 (15.7)	84.4 (74.8-90.6)
	T3	423	220 (52.0)	48.1 (43.1-52.9)
	T4	103	78 (75.7)	17.4 (9.2-27.8)
N stage	N0	219	38 (17.4)	84.2 (78.4-88.5)	< 0.001
	N1	184	63 (34.2)	66.0 (58.2-72.6)
	N2	150	87 (58.0)	38.7 (30.3-47.1)
	N3	175	139 (79.4)	17.3 (11.7-23.9)
TNM	I	137	12 (8.8)	90.6 (83.9-94.6)	< 0.001
	II	278	92 (33.1)	68.3 (62.1-73.6)
	III	313	223 (71.2)	25.8 (20.7-31.2)
Lymphovascular invasion	Negative	213	38 (17.8)	83.0 (77.0-87.6)	< 0.001
	Positive	511	287 (56.2)	42.6 (38.1-47.0)
Neural invasion	Negative	328	100 (30.5)	70.2 (64.6-75.0)	< 0.001
	Positive	396	225 (56.8)	41.1 (36.0-46.2)
Chemotherapy	No	488	218 (44.7)	54.8 (50.0-59.3)	0.054
	FOLFOX-4	136	63 (46.3)	52.1 (43.2-60.3)
	XELOX	73	28 (38.4)	61.7 (49.1-72.0)
	Other	38	25 (65.8)	34.0 (19.1-49.4)
Helicobacter pylori	Negative	228	109 (47.8)	49.8 (42.7-56.4)	0.364
	Positive	503	222 (44.1)	56.1 (51.4-60.4)

^aSome of the variables have missing values (The missing number was 4 for the variable of WHO type, 18 for differentiation, 7 for T stage, 7 for N stage, 7 for TNM stage, 11 for lymphovascular invasion, 11 for neural invasion, and 4 for Helicobacter pylori, respectively).

^bP was computed by log-rank test.